ヤヌスキナーゼ (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "ヤヌスキナーゼ" in Japanese language version.

refsWebsite
Global rank Japanese rank
4th place
24th place
2nd place
6th place
5,225th place
low place
6,690th place
394th place
7,208th place
low place

clinicaltrials.gov (Global: 5,225th place; Japanese: low place)

doi.org (Global: 2nd place; Japanese: 6th place)

  • “Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses”. Cell 93 (3): 373–83. (1998). doi:10.1016/S0092-8674(00)81166-6. PMID 9590172. 
  • “TYK2 is a key regulator of the surveillance of B lymphoid tumors”. J. Clin. Invest. 114 (11): 1650–8. (2004). doi:10.1172/JCI22315. PMC 529282. PMID 15578097. https://pmc.ncbi.nlm.nih.gov/articles/PMC529282/. 
  • Craiglow, B. G.; King, B. A. (2015). “Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy”. JAMA Dermatology 151: 1110–2. doi:10.1001/jamadermatol.2015.1520. PMID 26107994. 

gizmag.com (Global: 7,208th place; Japanese: low place)

nih.gov (Global: 4th place; Japanese: 24th place)

pubmed.ncbi.nlm.nih.gov

  • “Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses”. Cell 93 (3): 373–83. (1998). doi:10.1016/S0092-8674(00)81166-6. PMID 9590172. 
  • “TYK2 is a key regulator of the surveillance of B lymphoid tumors”. J. Clin. Invest. 114 (11): 1650–8. (2004). doi:10.1172/JCI22315. PMC 529282. PMID 15578097. https://pmc.ncbi.nlm.nih.gov/articles/PMC529282/. 
  • Craiglow, B. G.; King, B. A. (2015). “Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy”. JAMA Dermatology 151: 1110–2. doi:10.1001/jamadermatol.2015.1520. PMID 26107994. 

pmc.ncbi.nlm.nih.gov

pmda.go.jp (Global: 6,690th place; Japanese: 394th place)

info.pmda.go.jp